Magnus Sjogren, M.D., PhD, Associate Professor is new Chief Medical Officer at DiaGenic ASA
Dr. Sjogren joins DiaGenic as CMO from 1st September 2011 and will be part of the management team and responsible for the global clinical diagnostic programs and strategies of DiaGenic.
Prior to joining DiaGenic ASA he was Vice President Global Exploratory Development at UCB Pharma SA in Belgium and UK and before that has had executive and senior scientific positions at Schering-Plough, Organon and AstraZeneca. He is Associate Professor since 2002 with a PhD in Clinical Psychiatry in 1999 at Gothenburg University, Sweden.
He is a trained Psychiatrist and an author of more than 200 scientific publications and has been invited speaker at numerous International conferences. Dr. Sjogren earned his MD at the Health University in Linkoping and was further educated at Gothenburg University and has been affiliated to Karolinska Institute. His scientific work has been focused on clinical Neuroscience research topics including diagnostic biomarkers.
"I am very pleased that Magnus Sjogren now joins our senior management team", says CEO Erik Christensen. "This strengthening of our pharma and biomarker capabilities demonstrates DiaGenic's dedication to capitalize on our product portfolio by entering into collaboration with major pharma companies".
Contact:
Erik Christensen, CEO
Telephone: 47 95939918
e-mail: erik.christensen@diagenic.com
About DiaGenic ASA
DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts of the body. DiaGenic has developed and CE marked two blood based diagnostic tests, BCtect® for early breast cancer detection and ADtect® for early detection of Alzheimer’s Disease. The company protects its technology through an extensive patent portfolio. DiaGenic promotes its products towards leading pharmaceutical and imaging companies, and towards clinicians. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com